Single Agent Versus Combination Chemotherapy to Treat High-risk Elderly With Non-small Cell Lung Cancer
Status:
Terminated
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
This study will enroll elderly patients with advanced non-small cell lung cancer who are at
high risk of developing chemotherapy toxicity (side effects). Patients will receive treatment
with either a platinum-based doublet chemotherapy with carboplatin/nab-paclitaxel or single
agent nab-paclitaxel of chemotherapy. Response to treatment and treatment toxicity will be
compared in the two treatment groups to determine the best treatment strategy for this group
of patients.